EAM Investors’s Design Therapeutics DSGN Stock Holding History

EAM Investors’s Portfolio DSGN Stock Details DSGN Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q1	$840K	Hold	78,949	–	–	0.1%	225
2025 Q4	$741K	Buy	+78,949	New	+$618K	0.08%	236

Other funds holding DSGN

SR One Capital Management Wayne, Pennsylvania $915M AUM 209.71% 1-Year Est. Return

RA Capital Management Boston, Massachusetts $9.44B AUM 157.3% 1-Year Est. Return

Point72 Asset Management

Point72 Asset Management Stamford, Connecticut $78.1B AUM 55.25% 1-Year Est. Return

Baker Bros. Advisors New York $17.4B AUM 131.5% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Logos Global Management San Francisco, California $2B AUM 444.09% 1-Year Est. Return

Driehaus Capital Management Chicago, Illinois $13.6B AUM 173.98% 1-Year Est. Return

Vivo Capital Palo Alto, California $1.2B AUM 911.44% 1-Year Est. Return

Almitas Capital Santa Monica, California $443M AUM 42.36% 1-Year Est. Return

Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM

EAM Investors's DSGN Position: Q1 2026 in Review

EAM Investors held its Design Therapeutics (DSGN) position steady in Q1 2026 at 78,949 shares worth $840K. The position accounts for 0.1% of the portfolio, ranked #225.

EAM Investors first reported a position in DSGN in Q4 2025 and has held it in 2 quarters since. 125 funds tracked by Wall St. Rank hold DSGN as of Q1 2026.

EAM Investors held 78,949 shares of Design Therapeutics worth $840K as of Q1 2026.
EAM Investors left its Design Therapeutics share count unchanged in Q1 2026.
Design Therapeutics made up 0.1% of EAM Investors's portfolio in Q1 2026, its #225 holding.
EAM Investors first reported a position in Design Therapeutics in Q4 2025 and has held it in 2 quarters since.
125 funds tracked by Wall St. Rank held Design Therapeutics as of Q1 2026.

Based on EAM Investors's 13F filing for Q1 2026, filed 13 May 2026.